Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan ...

As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with concomitant ixekizumab and tirzepatide met PsA and weight reduction endpoints. Safety data ...

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. Elaine Chen covers biotech, co-writes The Readout ...

Medicare may cover Taltz (ixekizumab) if you have a plan with prescription drug coverage, such as a Part D plan or a Medicare Advantage (Part C) plan. Taltz is a brand-name biologic drug that doctors ...

Jan 8 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis ...